Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.

Nature biotechnology - 1 Jun 2005

Liu Shihui, Redeye Vivien, Kuremsky Jeffrey G, Kuhnen Marissa, Molinolo Alfredo, Bugge Thomas H, Leppla Stephen H

Abstract excerpt

Anthrax toxin protective antigen (PrAg) forms a heptamer in which the binding site for lethal factor (LF) spans two adjacent monomers. This suggested that high cell-type specificity in tumor targeting could be obtained using monomers that generate functional LF-binding sites only through intermolecular complementation. We created PrAg mutants with mutations affecting different LF-binding subsites and containing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Bacterial
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Toxins

Share to Binding Sites

Share to Cell Line, Tumor

Share to Drug Delivery Systems

Share to Drug Screening Assays, Antitumor

Share to Protein Engineering

Source

Open in PubMed Open full text

Identifiers

PMID: 15895075
DOI: 10.1038/nbt1091
PMCID: PMC2405912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.PMID 15895075Read ↗

Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.Semantic proximity Read ↗

Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.Semantic proximity Read ↗

Catalytically inactive anthrax toxin(s) are potential prophylactic agents.Semantic proximity Read ↗

Direct imaging of anthrax intoxication in animals reveals shared and individual functions of CMG-2 and TEM-8 in cellular toxin entrySemantic proximity Read ↗

An approach to characterizing single-subunit mutations in multimeric prepores and pores of anthrax protective antigen.Semantic proximity Read ↗

Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.Semantic proximity Read ↗

A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.Semantic proximity Read ↗

Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.Semantic proximity Read ↗

Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsSemantic proximity Read ↗

Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.Semantic proximity Read ↗

Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.Semantic proximity Read ↗

Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.